Epoetin alfa-epbx: a new entrant into a crowded market. a historical review of the role of erythropoietin stimulating agents and the development of the first epoetin biosimilar in the United States
2020
Introduction: Erythropoietin stimulating agents (ESAs) have been established both to correct anemia and provide the clinical benefits of increased exercise capacity, reduced transfusion requirement...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
42
References
0
Citations
NaN
KQI